SHIKARI® ELISA Kits:
Pioneering Biological-Drug Monitoring

134 Products. 45 Biological Drugs. One Comprehensive Portfolio—Evolving Since 2008.

Explore drug-level, anti-drug antibody and neutralising-antibody assays designed for laboratories, researchers and industry teams working across a broad range of biological therapies.

Browse Products Request a Quote

Since 2008, SHIKARI® has reflected a simple idea: trace and catch what matters in biological-drug monitoring research.

SHIKARI® — meaning “hunter.”

European Commercial & R&D&I Headquarters · Barcelona Manufacturing & Operations · Ankara

Trace & Catch — SHIKARI® visual with a fox following tracks through snow

24+

Years of Experience

134

SHIKARI® Products

Biological Drugs

200+

Documented Research Records

Choose Your Assay

Explore Our Product Portfolios

Browse All Products →

Flagship Portfolio

SHIKARI® Kits

134 research-use products covering 45 biological drugs, with assays for drug levels, anti-drug antibodies, free and total antibodies, and neutralising antibodies.

134 Products 45 Drugs Drug · ADA · NAb

Browse SHIKARI® assays

16 Research Assays

CoronaHunter® Kits

SARS-CoV-2 antibody research assays covering IgG, IgA, IgM and IgE across multiple viral-antigen targets, with quantitative reporting defined in the product documentation.

16 Kits IgG/IgA/IgM/IgE Quantitative

Browse CoronaHunter® kits

Product Development

Custom ELISA Development

Custom assay development for biosimilars and biologics, from antigen sourcing and monoclonal-antibody production through assay development and manufacturing.

Biosimilars Custom Assays ISO 13485:2016

Explore product development

Understanding the Research Challenge

Why Biological-Drug Monitoring Research Matters

Biological medicines have transformed the treatment of many serious diseases, yet drug exposure and immune responses can vary considerably between individuals. Differences in circulating drug levels and the development of anti-drug antibodies—including neutralising antibodies—may affect pharmacokinetics and observed treatment response.

SHIKARI® research-use assays enable laboratories, academic researchers, and pharmaceutical and biotechnology teams to investigate biological-drug levels, anti-drug antibodies and neutralising antibodies across a broad range of biological therapies.

For Research Use Only (RUO). Not for use in diagnostic procedures.

Who We Are

Scientific Heritage Behind the SHIKARI® Portfolio

Matrix Biotek combines scientific expertise, established manufacturing capabilities and an international outlook to provide biological-drug monitoring research products.

Our team pioneered the development, manufacture and commercialization of biological-drug monitoring kits in 2008. That experience underpins today’s SHIKARI® portfolio and its continued product development.

European commercial and R&D&I activity in Barcelona works alongside established product development, manufacturing and operations in Ankara—connecting customers with reliable products, technical information and responsive commercial support.

Discover Our Scientific Heritage

ISO 13485:2016Ankara manufacturing quality system

Product ExpertiseGuidance across drug-level, ADA and NAb assay formats

45 Biological DrugsBroad coverage across drug, ADA and NAb research

Commercial SupportProduct information and quotations from Barcelona and Ankara

Product Selection & Ordering

Choose the Right Assay. Request a Quote.

Browse the SHIKARI® portfolio by biological drug and assay type. Each detailed product page presents available formats, catalogue references and verified technical-source links.

If you need help comparing products, our team can provide product information, availability and a quotation. Scientific and technical support remains available as a separate route when required.

Browse SHIKARI® Products Request a Quote

R&D&I

EU-Based R&D&I Programmes

Matrix Biotek develops European research programmes spanning infectious diseases, inflammation biomarkers, autoimmunity, and post-COVID-19 vascular disorders.

Our collaborative and grant-backed work includes programmes with LEITAT Technological Center, the CandidaHunter® nanotechnology project (EU Horizon 2020 Phase 1, Grant ID 877651), research into serological markers for Crohn's disease, and the Long-COVID Screening Pathway pilot.

Discover Our Pipeline

Infectious Diseases Invasive fungal infections (Candida spp.) & host immunity

Inflammation & Biomarkers IBD, oxidative stress & chronic disease research

Systemic Disorders Inflammation-driven autoimmunity & post-COVID-19

Resources for Your Work

Product Information & Scientific Resources

Open product information and scientific resources directly — designed to help researchers and laboratories identify the relevant assay and understand the science behind biological-drug monitoring.